Effect of DHEA on Patients With Poor Ovarian Responds

Launched by THE AFFILIATED HOSPITAL OF INNER MONGOLIA MEDICAL UNIVERSITY · Apr 28, 2015

Keywords

ClinConnect Summary

This clinical trial is looking at the effects of a medication called DHEA (dehydroepiandrosterone) on women who have difficulty becoming pregnant due to low ovarian reserve, which means their ovaries do not produce enough eggs. The study aims to see if taking DHEA can improve outcomes for women undergoing in vitro fertilization (IVF) treatment.

To be eligible for this trial, participants need to be women under the age of 42 who have regular menstrual cycles and are planning to undergo IVF. They should also have a history of poor ovarian response, which could be indicated by factors such as age or previous IVF attempts that resulted in few eggs. Those who have had certain medical treatments, like chemotherapy, or have specific conditions like polycystic ovarian syndrome, unfortunately cannot participate. If you join the study, you can expect to take DHEA and then be evaluated on how it affects your IVF results. This trial is currently recruiting participants, so it’s a great opportunity for eligible women seeking support with their fertility journey.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Indicated for IVF treatment according to our standard department protocol
• • Age \< 42
• • Regular menstrual cycles (21-35 days)
• Poor ovarian responders are defined according to the Bologna criteria fulfilling 2 out of 3 of the following:
• • Advanced maternal age (≥40) or any other genetic or acquired risk factor for POR
• • Previous poor ovarian response (POR) (≤3 oocytes with a conventional stimulation protocol using at least 150IU gonadotrophins per day)
• • Abnormal ovarian reserve test (i.e. AFC \< 5-7 or AMH \< 0.5-1.1ng/ml). Alternatively, two episodes of POR after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal ORT.
• Exclusion Criteria:
• • Previous chemotherapy or pelvic irradiation
• • Polycystic ovarian syndrome or polycystic ovaries
• • On hormonal supplementation for any indication at the time of recruitment (e.g. estrogen, testosterone or DHEA)